ReviewFrontiers in immunology2026
Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome.International journal of molecular sciences · 2026Article
- Review
- Jiedu-Shengji Ointment promotes diabetic wound repair by inhibiting the NLRP3/Caspase-1/GSDMD signaling pathway and regulating macrophage function.Frontiers in immunology · 2026Article
- Integrated dual transcriptome sequencing and experimental validation reveal potential mechanisms of baicalin againstFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptor 4 (TLR4) is a pattern recognition receptor that binds to pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs). Binding of exogenous or endogenous ligands activates the TLR4 pathway and induces the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β and type 1 interferons including IFN-α and IFN-β. TLR4 plays a vital role in host defense against Gram-negative bacterial infections by recognizing lipopolysaccharides (LPS) and inducing inflammatory mediators to clear infection. However, there is emerging evidence that excessive TLR4 activation may be pathogenic in human diseases affecting the central nervous system, cardiovascular, respiratory and metabolic systems, thereby promoting inflammation and autoimmunity. In some diseases, the is conflicting evidence regarding pathogenic versus protective roles. Several TLR4 targeted therapeutics have been developed and studied in animal models, however many of these therapeutics including Eritoran and TAK-242 did not prove to be effective in clinical trials. Overall, TLR4 exhibits context-dependent protective and pathogenic roles across infectious and non-infectious diseases, reflecting the complexity of its signaling in human health and disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.